News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2013

Correction Notification: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Correction of the announcement: Epigenomics AG increases share capital

PDF 29 KB   Correction notifaction of the announcement of Epigenomics AG (Frankfurt Prime Standard: ECX; ISIN: DE000A1K0516) according to § 15 WpHG as of October 28, 2013 – 9:00 pm CET Epigenomics erroneously announced yesterday its intention to increase its share capital by up to EUR 4,136,720.00 from the authorized capital. Instead, Epigenomics plans […]

Read more

Ad Hoc Epigenomics AG successfully completes private placement of newly issued shares

PDF 28 KB   Not for distribution in the United States Berlin, Germany, October 29, 2013 – Today the Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX;ISIN: DE000A1K0516) with the approval of the Supervisory Board has resolved on the increase of the Company’s share capital by EUR 660,260.00 from the authorized capital 2013/I against […]

Read more

Epigenomics and BioChain enter into broad strategic collaboration in China and investment into Epigenomics

28.10.2013 | 131028_Press_release_Epigenomics_AG_Biochain BioChainto acquire exclusive development and commercial Septin9 license for China BioChain to invest US$ 1.3 m in Epigenomics Initiation of large clinical study with the goal of gaining China Food and Drug Administration (CFDA) approval 5,000 Epi proColon® tests ordered for Q4 delivery Establishment of a broad research collaboration

Read more

Ad Hoc: Epigenomics AG increases share capital

PDF 58 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that the Company’s Executive Board today with the approval of the Supervisory Board has resolved on an increase of the Company’s share capital by up to EUR 4,136,720 from the authorized capital. This capital increase follows a previous capital increase, published via ad […]

Read more

Ad hoc: Epigenomics and BioChain sign agreement for broad strategic collaboration in China

PDF 43 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that it has signed an agreement with BioChain regarding a broad strategic collaboration of both companies. BioChain is a leading clinical diagnostics company in cancer and genetic tests in China and the US. As part of the agreed collaboration, which significantly expands the […]

Read more

Ad hoc: Epigenomics issues new shares to BioChain – Investment follows agreement on broad strategic collaboration in China

PDF 39 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that BioChain and certain of its shareholders will invest US$ 1.3 million (EUR 0.94 million) into the Company by subscribing 217,935 newly issued shares. This investment follows the signing of an agreement regarding a broad strategic collaboration of both companies announced today. Executive […]

Read more